Showing results (361-370 of 491) with videos related to
Sort By:
Pageof 50
Journal of the American Heart Association|March 5, 2015
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trialDaniel E Singer, Anne S Hellkamp, Zhong Yuan, et al.Clinical Chemistry|May 19, 2017
Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary SyndromeMark Y Chan, Megan L Neely, Matthew T Roe, et al.Journal of Thrombosis and Thrombolysis|June 27, 2018
Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary interventionGerald Chi, Megan K Yee, Arzu Kalayci, et al.European Heart Journal Open|June 9, 2023
Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AFAlan John Camm, Jan Steffel, Saverio Virdone, et al.The American Journal of Medicine|December 2, 2014
Sensitive troponin assay and the classification of myocardial infarctionAnoop S V Shah, David A McAllister, Rosamund Mills, et al.Journal of the American College of Cardiology|November 26, 2002
Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failureMark T Kearney, Keith A A Fox, Amanda J Lee, et al.JAMA|June 10, 2004
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registryKim A Eagle, Michael J Lim, Omar H Dabbous, et al.The American Journal of Cardiology|August 18, 2018
Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events)Mali D Worme, Mary K Tan, David W J Armstrong, et al.Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.Lancet (London, England)|August 17, 2010
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trialEric J Topol, Marie-Germaine Bousser, Keith A A Fox, et al.Pageof 50